Avita Medical (ASX:AVH) has advised its new randomised skin trial shows that its ReCell product has healed donors 30 per cent faster.
The regenerative medical company’s study was on 106 patients who received skin grafts.
It’s the company’s third positive clinical trial of late and it found superior wound healing and improved aesthetic appearance.
Avita Medical says its pleased the data shows its ReCell product, can be used to both reduce patient trauma and heal patients much quicker.
Shares in Avita Medical (ASX:AVH) are trading flat at 8 cent.